6533b872fe1ef96bd12d3a59

RESEARCH PRODUCT

Three-arm randomized phase II study evaluating oral vinorelbine plus capecitabine versus paclitaxel plus gemcitabine versus docetaxel plus gemcitabine as first-line chemotherapy in patients with metastatic breast cancer: Final results (NorCap-CA223 trial)

Philippe BougnouxC. F. SlabberG. VillanovaKadri AltundagRustem KhasanovAgustí BarnadasPatricia DodykSaverio CinieriMarcus SchmidtAnn VandebroekDaniel RauchDar-ren ChenNicole Tubiana-mathieuMichiel BothaMaria Jose GodesUgur CoskunJ. CárdenasArlene ChanJavier Castellanos DiezSilvia Lazzarelli

subject

OncologyCancer Researchmedicine.medical_specialtybusiness.industryStandard treatmentCombination chemotherapymedicine.diseaseVinorelbineMetastatic breast cancerGemcitabineCapecitabinechemistry.chemical_compoundOncologyDocetaxelPaclitaxelchemistryInternal medicinemedicinebacteriaskin and connective tissue diseasesbusinessmedicine.drug

description

1044 Background: Combination chemotherapy (CT) is among the standard treatment options in metastatic breast cancer (MBC), especially in patients (pts) with visceral metastases or need of rapid symp...

10.1200/jco.2014.32.15_suppl.1044https://avesis.gazi.edu.tr/publication/details/1e3a5b5e-ae98-48c3-8c7d-2480741d1cac/oai